{"filing":{"accession_number":"0001213900-26-073213","cik":"0001937993","ticker":"CVKD","company_name":"Cadrenal Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"ea0296328-8k_cadrenal.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026073213/ea0296328-8k_cadrenal.htm"},"events":[{"id":14743,"run_id":13135,"accession_number":"0001213900-26-073213","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The filing discloses the appointment of John P. Sharp as Interim Chief Financial Officer on June 25, 2026, replacing Quang X. Pham. While the section also includes a director resignation (Steven Zelenkofske) and board realignment, the principal disclosed action centers on the CFO appointment, which is material to investors as it affects the company's financial leadership. The detailed biography and compensation terms ($455/hour for up to 24 hours/week under a Master Services Agreement) underscore the significance of this executive appointment.","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12269,"accession_number":"0001213900-26-073213","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of John P. Sharp as Interim Chief Financial Officer on June 25, 2026, replacing Quang X. Pham. While the section also includes a director resignation (Steven Zelenkofske) and board realignment, the principal disclosed action centers on the CFO appointment, which is material to investors as it affects the company's financial leadership. The detailed biography and compensation terms ($455/hour for up to 24 hours/week under a Master Services Agreement) underscore the significance of this executive appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T21:20:46.402793+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12269,"accession_number":"0001213900-26-073213","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of John P. Sharp as Interim Chief Financial Officer on June 25, 2026, replacing Quang X. Pham. While the section also includes a director resignation (Steven Zelenkofske) and board realignment, the principal disclosed action centers on the CFO appointment, which is material to investors as it affects the company's financial leadership. The detailed biography and compensation terms ($455/hour for up to 24 hours/week under a Master Services Agreement) underscore the significance of this executive appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T21:20:46.402793+00:00","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-06-29"}]}